Bayer Ag · XETR:BAYN
Bayer — Investor Day (March 2021)
21 slides from Bayer's investor day presentation, Mar 10, 2021
Slide 1: Cell- and Gene-Therapies
Cell- and Gene- Therapies /////////// Capital Markets Day March 10-11, 2021 Wolfram Carius Head of C> at Bayer Pharmaceuticals Sheila Mikhail CEO & Co-Founder of Asklepios BioPharmaceutical Emile Nuwaysir CEO of BlueRock Therapeutics 1
Slide 2: Cautionary Statements Regarding Forward-Looking Information
Cautionary Statements Regarding Forward-Looking Information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the ac
Slide 3: Sheila Mikhail
Sheila Mikhail CEO & Co-Founder of Asklepios BioPharmaceutical 3
Slide 4: Sheila Mikhail, JD, MBA
Sheila Mikhail, JD, MBA CEO & Co-founder
Slide 5: AskBio at-a-glance
AskBio at-a-glance Over 350 professionals operating in 5 countries Therapeutics Contract Manufacturing Cash Flows & Royalties Our scientific leaders pioneered the AAV gene Payments from sale of Technology/Programs therapy field AskBio’s R. Jude Samulski, PhD Kathy High, MD technology is Chief Scient
Slide 6: Introduction to gene therapy
Introduction to gene therapy Treating Disease by Fixing the Cause 1 2 3 4 Therapeutic Therapeutic Gene Protein Production Development Delivery Transfer & Therapeutic Effect Nucleus DNA Gene Encapsulated (Gene) in AAV Target Cell Functional Protein AAV - The Superior Vector Delivery System Good Affec
Slide 7: Leading AAV therapeutics toolbox
Leading AAV therapeutics toolbox TECHNOLOGY Novel Viral Vectors Synthetic Promoters Improved tissue targeting Customized promoters Higher cell transduction On/off expression control 800+ Patents/Patent Applications Synthetic dbDNA™ Pro10™ HEK 293 cell suspension Assemble DNA Scaled manufacturing seq
Slide 8: Strong therapeutic pipeline with potential for multiple products
Strong therapeutic pipeline with potential for multiple products Disease Discovery Preclinical Phase 1/2 Patient population Next Milestone Pompe disease ~20-25k in U.S. Ph 2/3 Congestive heart failure ~5M in U.S. Dose Escalation Parkinson’s disease ~1M in U.S. Read out Cohort 1 Multiple system atrop
Slide 9: Why partner with Bayer?
Why partner with ? Science Focused Governance Culture Bayer’s purpose “Science for a Better Life” Governance By allowing us to stay independent, we is consistent with our science driven can advance drugs with the nimbleness culture and focus of a smaller structure Cardiovascular Experience Small Mol
Slide 10: AskBio
Slide 11: Emile Nuwaysir
Emile Nuwaysir CEO of BlueRock Therapeutics 11
Slide 12: An Entirely New Generation of Cellular Medicines
An Entirely New Generation of Cellular Medicines
Slide 13: Our Mission
Our Mission DEVELOP AUTHENTIC CELLULAR MEDICINES TO REVERSE DEVASTATING DISEASES.
Slide 14: Pioneering a novel cell+gene platform
Pioneering a novel cell+gene platform REPLACE ENGINEER Cells Cells RESTORE DELIVER Function Payload REVERSE TREAT Disease Rare and Common • Authentic Cell • Engineered Replacement • Authentic Cells Focused on three therapeutic areas: neurology, immunology, and cardiology
Slide 15: Platform Based on Universal Stem Cells
Platform Based on Universal Stem Cells Enables Both Authentic and Engineered Cellular Medicines Authentic Cell Replacement Induced Infinite Pluripotent Universal iPSC for Expansion, Healthy Donor Stem Cell (iPSC) “Off-the-Shelf” Use Highly Scalable (Dopaminergic neurons) Differentiate Engineered Aut
Slide 16: BlueRock Pipeline
BlueRock Pipeline Advancing a Deep Pipeline of cell+gene Therapies Parkinson’s Disease Demyelinating Disorders Neurodegenerative Diseases Heart Failure cell+gene medicines Atrial Fibrillation Hirschsprung’s Disease Immunology Tolerance & Fibrosis Inflammation & Tolerance Oncology 16
Slide 17: Parkinson's Disease | High Unmet Medical Need
Parkinson’s Disease | High Unmet Medical Need A Debilitating Disease Impacting a Large Current Treatment Options Are Not Patient Population Adequate • Medications, effective at early stages, become less and less effective with disease progression • Annual WW sales of ~$2.8B by 2019 • DBS carries the
Slide 18: Best-in-Class Neural Cell Differentiation Expertise
Best-in-Class Neural Cell Differentiation Expertise BlueRock’s Team Pioneered the Derivation of Dopaminergic Neurons Pluripotent “Early” Neuronal Novel FOXA2 Midbrain Dopamine Stem Cell Stem Cell Floor Plate Method Neuron Over $23M in NYSTEM grants supported the advancement of Studer’s PD cell thera
Slide 19: Groundbreaking Phase 1 Parkinson's Trial Design
Groundbreaking Phase 1 Parkinson’s Trial Design: Evaluation of Safety, Tolerability and Efficacy Takeaways Trial Design • Single-center, open label, Phase I trial assessing DA01 authentic cell therapy for Advanced Parkinson’s Disease • Significant clinical trial protocol improvements over prior cell
Slide 20: Develop Authentic Cellular Medicines to Reverse Devastating Diseases
DEVELOP AUTHENTIC CELLULAR MEDICINES TO REVERSE DEVASTATING DISEASES.
Slide 21: Cell- and Gene-Therapies
Cell- and Gene- Therapies /////////// Capital Markets Day March 10-11, 2021 Wolfram Carius Head of C> at Bayer Pharmaceuticals Sheila Mikhail CEO & Co-Founder of Asklepios BioPharmaceutical Emile Nuwaysir CEO of BlueRock Therapeutics 21